Noteworthy among these findings include a missense variant in LAG3 (P67T), an inhibitory immune receptor for which inhibitors have been recently approved as immunotherapy in advanced melanoma (Tawbi et al. 2022; Long et al. 2023). The gene discussed is LAG3; the disease is melanoma.